<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-9339</journal-id>
<journal-title><![CDATA[Odontoestomatología]]></journal-title>
<abbrev-journal-title><![CDATA[Odontoestomatología]]></abbrev-journal-title>
<issn>1688-9339</issn>
<publisher>
<publisher-name><![CDATA[Facultad de Odontología - Universidad de la República]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-93392021000201406</article-id>
<article-id pub-id-type="doi">10.22592/ode2021n37e406</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento conservador de osteonecrosis maxilar asociada a medicamentos refractaria mediante el uso de protocolo PENTO: reporte de un caso]]></article-title>
<article-title xml:lang="pt"><![CDATA[Tratamento conservador da osteonecrose maxilar associada a medicamentos refratários usando o protocolo PENTO: relato de um caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Conservative treatment of refractory medication-related osteonecrosis of the jaw using the PENTO protocol: A case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Melián Rivas]]></surname>
<given-names><![CDATA[Andrés Noah]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rojas Donaire]]></surname>
<given-names><![CDATA[Javiera Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Servicio de Salud Metropolitano Oriente Centro de Urgencias de Ñuñoa Unidad de Urgencia Odontológica]]></institution>
<addr-line><![CDATA[Santiago ]]></addr-line>
<country>Chile</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<volume>23</volume>
<numero>38</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-93392021000201406&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-93392021000201406&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-93392021000201406&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Paciente de 78 años consulta por sangrado sin resolución, a nivel del reborde alveolar maxilar izquierdo. Con antecedentes de metástasis óseas tratadas con ácido zoledrónico endovenoso discontinuado por alta médica y tratamiento quirúrgico previo de osteonecrosis maxilar en sitio afectado. Se observó disrupción de continuidad con inflamación a nivel del reborde óseo, con salida de contenido hemático, purulento y necrótico. Radiográficamente se observó radiolucidez difusa y osteolítica del área afectada y tejido necrótico a nivel microscópico. Se realizó aseo del área afectada, enjuagues de clorhexidina 0,12%, administración de amoxicilina/acido clavulánico y de pentoxifilina 400 mg cada 12 horas y tocoferol 1000 UI cada 24 horas. Se evaluó al mes, donde se discontinua antibioterapia y se mantiene régimen establecido con controles cada 2 semanas. A los 6 meses se evidencia resolución completa, con cicatrización de la mucosa y del tejido óseo sin recidiva.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo Paciente de 78 anos consultado por sangramento sem resolução, ao nível do rebordo alveolar superior esquerdo. Com história de metástases ósseas tratadas com ácido zoledrônico endovenoso descontinuado por alta médica e tratamento cirúrgico prévio de osteonecrose maxilar no local afetado. Foi observada interrupção da continuidade com inflamação ao nível da crista óssea, com extravasamento de sangue, conteúdo purulento e necrótico. Radiograficamente, radioluscência difusa e osteolítica da área afetada e tecido necrótico foram observadas ao nível microscópico. A área afetada foi limpa, enxágue com clorexidina 0,12%, amoxicilina / ácido clavulânico e 400 mg de pentoxifilina a cada 12 horas e 1000 UI de tocoferol a cada 24 horas. Foi avaliado em um mês, quando a antibioticoterapia é descontinuada e um regime estabelecido é mantido com controles a cada 2 semanas. Aos 6 meses, é evidenciada resolução completa, com cicatrização da mucosa e do tecido ósseo sem recorrência.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract A 78-year-old patient seeks care for unresolved bleeding on the left maxillary alveolar ridge. He had a history of bone metastasis treated with IV zoledronic acid, which was discontinued after medical discharge and previous surgical treatment of osteonecrosis of the jaws in the affected site. Continuity disruption with inflammation at the bone ridge was observed, with blood, purulent, and necrotic exudate. The radiograph showed diffuse and osteolytic radiolucency of the affected area, and necrotic tissue was detected at a microscopic level. The affected area was rinsed with 0.12% chlorhexidine, 400 mg amoxicillin/clavulanic acid and pentoxifylline was administered every 12 hours, and tocopherol 1000 IU every 24 hours. The area was evaluated after a month. Antibiotic therapy was discontinued, and the patient continued to be monitored every two weeks. At six months, there is complete resolution, and mucosal and bone tissue healed without recurrence.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Osteonecrosis de los maxilares asociada a medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Bifosfonatos]]></kwd>
<kwd lng="es"><![CDATA[Pentoxifilina]]></kwd>
<kwd lng="es"><![CDATA[Tocoferol]]></kwd>
<kwd lng="pt"><![CDATA[Osteonecrose da mandíbula associada a medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[Bisfosfonatos]]></kwd>
<kwd lng="pt"><![CDATA[Pentoxifilina]]></kwd>
<kwd lng="pt"><![CDATA[Tocoferol]]></kwd>
<kwd lng="en"><![CDATA[Medication-Related Osteonecrosis of the Jaw]]></kwd>
<kwd lng="en"><![CDATA[Bisphosphonates]]></kwd>
<kwd lng="en"><![CDATA[Pentoxifylline]]></kwd>
<kwd lng="en"><![CDATA[Tocopherol]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heifetz-Li]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Abdelsamie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fielding]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Mulligan]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw]]></article-title>
<source><![CDATA[Oral Surg Oral Med Oral Pathol Oral Radiol]]></source>
<year>2019</year>
<volume>128</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>491-497.e2</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Govaerts]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Piccart]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ockerman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coropciuc]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Politis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjuvant therapies for MRONJ A systematic review]]></article-title>
<source><![CDATA[Bone]]></source>
<year>2020</year>
<volume>141</volume>
<numero>115676</numero>
<issue>115676</issue>
<page-range>115676</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruggiero]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Dodson]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Fantasia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Goodday]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aghaloo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mehrotra]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update]]></article-title>
<source><![CDATA[J Oral Maxillofac Surg]]></source>
<year>2014</year>
<volume>72</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1938-56</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sivolella]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lumachi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Stellini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Favero]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw an uncommon but potentially severe disease]]></article-title>
<source><![CDATA[Anticancer Res]]></source>
<year>2013</year>
<volume>33</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1793-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pakosch]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Papadimas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Munding]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kawa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kriwalsky]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab]]></article-title>
<source><![CDATA[Oral Maxillofac Surg]]></source>
<year>2013</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>303-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foncea]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[von Bischhoffshausen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Teuber]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Goñi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteonecrosis of the jaws]]></article-title>
<source><![CDATA[Rev Med Chil]]></source>
<year>2020</year>
<volume>148</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>983-91</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beth-Tasdogan]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Mayer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hussein]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zolk]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interventions for managing medication-related osteonecrosis of the jaw]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2017</year>
<volume>10</volume>
<page-range>CD012432</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martos-Fernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saez-Barba]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López-López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Estrugo-Devesa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Balibrea-Del-Castillo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bescós-Atín]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis a systematic review]]></article-title>
<source><![CDATA[Oral Surg Oral Med Oral Pathol Oral Radiol]]></source>
<year>2018</year>
<volume>125</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>431-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Eo]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Myoung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of pentoxifylline and tocopherol in jaw osteomyelitis]]></article-title>
<source><![CDATA[J Korean Assoc Oral Maxillofac Surg]]></source>
<year>2020</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-27</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lyons]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pentoxifylline - a review of its use in osteoradionecrosis]]></article-title>
<source><![CDATA[Br J Oral Maxillofac Surg]]></source>
<year>2017</year>
<volume>55</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>230-4</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cavalcante]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Tomasetti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw A systematic literature review]]></article-title>
<source><![CDATA[J Craniomaxillofac Surg]]></source>
<year>2020</year>
<volume>48</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1080-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Owosho]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Estilo]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Huryn]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Yom]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw an observational retrospective study of initial case series]]></article-title>
<source><![CDATA[Oral Surg Oral Med Oral Pathol Oral Radiol]]></source>
<year>2016</year>
<volume>122</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>455-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Wicknick]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Berenson]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Gorsky]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of bisphosphonate-associated osteonecrosis pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series]]></article-title>
<source><![CDATA[Oral Surg Oral Med Oral Pathol Oral Radiol Endod]]></source>
<year>2010</year>
<volume>110</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>593-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magremanne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reychler]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis]]></article-title>
<source><![CDATA[J Oral Maxillofac Surg]]></source>
<year>2014</year>
<volume>72</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>334-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pellecer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The efficacy of pentoxifylline/tocopherol combination in the treatment of osteoradionecrosis Pentoxifylline/tocopherol combination]]></article-title>
<source><![CDATA[Spec Care Dentist]]></source>
<year>2015</year>
<volume>35</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>268-71</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
